Gapping up
In reaction to strong earnings/guidance:
- EME +5.9%, MCK +4.6%, MPLX +4.5%, LGND +4.1%, MCY +4.1%, GPN +3.1%, TKR +2.7%, BCC +2%, TSN +0.9%
M&A news:
- ZVO +24.4% (to sell Ashford University to a newly formed non-profit entity that will bear the name of The University of Arizona Global Camp)
- VAR +22.4% (to be acquired ty Siemens Healthineers for $177.50 per share)
- MPC +8.9% (agrees to sell Speedway to 7-Eleven for $21 bln; also reported earnings)
- MSFT +2.8% (to continue discussions on potential TikTok purchase in the United States)
Other news:
- ADT +96.7% (ADT and Google partner to create leading smart home security offering; Google to invest $450 million to acquire 6.6% ownership in ADT)
- IMUX +39.3% (reports Phase 2 EMPhASIS trial of IMU-838 met primary and key secondary endpoints)
- CBAY +29.9% (announces topline results from ENHANCE, a placebo-controlled, randomized, Phase 3 study evaluating the safety and efficacy of seladelpar for the treatment of primary biliary cholangitis)
- CODX +9.6% (Co-Diagnostics Technology to be used in FDA-authorized self-collected COVID-19 saliva test)
- BCRX +8.1% (granted FDA Fast Track designation for its oral Factor D inhibitor, BCX9930, for the treatment of paroxysmal nocturnal hemoglobinuria)
- VNDA +7.3% (FDA has accepted for priority review Vanda's applications for Smith-Magenis Syndrome)
- TNP +5.6% (files for $500 mln mixed securities shelf offering)
- INCY +5.4% (Incyte and MorphoSys receive FDA approval for Monjuvi in combination with Lenalidomide)
- NIO +5.1% (reports July deliveries increased 322.1% yr/yr to 3533 vehicles)
- ETON +4.9% (files for 3.5 mln share common stock offering by selling shareholder)
- LCI +4.2% (announced the launch of Cediprof, Inc.'s FDA approved Levothyroxine Sodium Tablets USP, under the companies recently announced interim exclusive supply and distribution agreement)
- GWPH +4% (FDA has approved Epidiolex oral solution to treat seizures associated with tuberous sclerosis complex in patients one year of age and older)
- OTIC +4% (announced an exclusive license agreement with KYORIN Pharma to develop, manufacture and commercialize a novel compound for the treatment of sensorineural hearing loss)
- ATRS +3.4% (entered into an exclusive distribution agreement with Lunatus Global Medical Supplies to distribute and promote the sale of XYOSTED in Saudi Arabia and the UAE)
- SPCE +3.3% (unveils Mach 3 aircraft design for high speed travel, and signs memorandum of understanding with Rolls-Royce)
- CERC +3.3% (receives FDA Orphan Drug Designation to CERC-006, a dual inhibitor of mTOR complexes 1 and 2 for the treatment of lymphatic malformations)
- RDHL +2.4% (replaces existing 2015 co-commercialization agreement with Daiichi Sankyo, Inc. for Movantik)
- NVS +1.8% (Cosentyx receives EU approval for first-line systemic treatment in pediatric psoriasis)
- LLY +1.8% (initiates Phase 3 trial of LY-CoV555 for prevention of COVID-19 at long-term care facilities in partnership with the national institute of allergy and infectious diseases)
- AAPL +1.7% (positive Barrons article)
- GSK +1.4% (GlaxoSmithKline and Sanofi in advanced discussions with EU to supply up to 300 mln doses of COVID-19 vaccine)
Analyst comments:
- UMC +7.6% (upgraded to Buy from Neutral at Goldman)
- MTX +6.5% (upgraded to Overweight from Neutral at JP Morgan)
- MGI +4.9% (upgraded to In-line from Underperform at Evercore ISI)
- MIRM +4.1% (initiated with a Buy at H.C. Wainwright)
- PINS +2.5% (upgraded to Buy from Hold at Pivotal Research Group)
- BLDR +2.1% (upgraded to Buy from Neutral at B. Riley FBR)
- QCOM +1.5% (upgraded to Outperform from Mkt Perform at Bernstein)
- FND +1.2% (upgraded to Buy from Neutral at BofA Securities)
- MRK +0.9% (upgraded to Buy from Neutral at Goldman)
- YUM +0.9% (upgraded to Buy from Hold at Deutsche Bank)